摘要
胃癌目前是全球发病率第五位的恶性肿瘤,在肿瘤致死率中居第三位。除曲妥珠单抗(Trastuzumab)以及雷莫芦单抗(Ramucirumab)的Ⅲ期临床实验获得阳性结果外,其他胃癌靶向治疗药物大多结果不甚理想或尚处于临床研究的早期阶段。文中主要综述了有潜在临床应用价值的胃癌驱动基因及其相关靶向药物的应用。包括抗人表皮生长因子受体2,表皮生长因子受体,成纤维细胞生长因子受体,肝细胞生长因子受体原癌基因MET,胰岛素样生长因子1受体以及血管内皮生长因子。
Gastric cancer is the fifth most common cancer and the third leading cause of death globally. Apart from the successful phase Ⅲ clinical trial of trastuzumab and Ramucirumab, other targeted therapies in gastric cancer （GC） have fallen short or still in early clinical development. In this review, we will summarize the most up to date information on many of the potential actionable ＂driver genes＂ in gastric cancer and the importance of using the optimal diagnostic test to select for these molecularly defined patients. We focus on the following aspects： HER-2, EGFR, FGFR, MET, IGF-1R and VEGF.
出处
《医学研究生学报》
CAS
北大核心
2014年第12期1318-1322,共5页
Journal of Medical Postgraduates
基金
国家自然科学基金(81370064)
江苏科技发展计划项目(BL2012001)
关键词
胃癌
靶向治疗
驱动基因
Gastric cancer
Molecular therapy
Driver genes
